Other Information
−Removed: Not applicable.
−Removed: Registrant’s
+Added: Insider Adoption or Termination of Trading Arrangements:
+Added: During the fiscal quarter ended March 31, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, except as described in the table below:
+Added: Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement
+Added: Greg Zante , Chief Financial Officer
+Added: February 2, 2024
+Added: Rule 10b5-1 trading arrangement
+Added: August 1, 2024 (1)
+Added: Marianne Mancini , Chief Operations Officer
+Added: February 1, 2024
+Added: trading arrangement
+Added: April 20, 2025 (1)
+Added: The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table.
Amended and Restated Certificate of Incorporation.
1 unchanged sentence
Form of Common Stock Certificate.
−Removed: Amendment No.
−Removed: 1 to At-the-Market Equity Offering Sales Agreement, dated as of July 26, 2023, by and among Viking Therapeutics, Inc., Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc., H.C.
−Removed: Wainwright & Co., LLC and BTIG, LLC.
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
2 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Inline XBRL Instance Document –
−Removed: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
+Added: Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
Inline XBRL Taxonomy Extension Schema Document.
5 unchanged sentences
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline Extensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, (iii) Consolidated Statements of Stockholders’
−Removed: Equity (Deficit) for the three and nine months ended September 30, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022, and (v) Notes to Consolidated Financial Statements.
+Added: (i) Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, (ii) Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023, (iii) Consolidated Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023, and (v) Notes to Consolidated Financial Statements.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Viking Therapeutics, Inc.
−Removed: October 25, 2023
+Added: April 24, 2024
/s/ Brian Lian, Ph.D.
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 25, 2023
+Added: April 24, 2024
/s/ Greg Zante
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.